Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $677,530.36 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 2,041 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total value of $677,530.36. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $7,058,797.44. This represents a 8.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Friday, February 13th, Kevin Joseph Fitzgerald sold 1,959 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $310.08, for a total value of $607,446.72.
• On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $370.33, for a total value of $848,055.70.
• On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded up $18.21 on Tuesday, hitting $332.61. The stock had a trading volume of 1,516,365 shares, compared to its average volume of 1,632,567. The company has a market capitalization of $44.11 billion, a price-to-earnings ratio of 194.51 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The firm has a 50-day moving average of $372.67 and a 200-day moving average of $424.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue was up 84.9% on a year-over-year basis. During the same period last year, the firm posted ($0.65) EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Thematics Asset Management purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $1,995,000. Mediolanum International Funds Ltd bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $11,389,000. Teacher Retirement System of Texas grew its stake in Alnylam Pharmaceuticals by 3.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after buying an additional 1,123 shares during the last quarter. Rakuten Investment Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $14,205,000. Finally, Generali Asset Management SPA SGR increased its stake in shares of Alnylam Pharmaceuticals by 6,368.0% during the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after acquiring an additional 3,184 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Stifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Needham & Company LLC lowered their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Finally, Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective on the stock. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.